Pharmaceutical

Medical Care Technologies Inc. Introduces AI Facial Health Risk Estimator for Cardiovascular Disease Detection

MESA, ARIZONA / ACCESS Newswire / September 23, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced the launch…

3 months ago

Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating

COEP Balances Revenue Generation With Breakthrough Cell Therapy DevelopmentBRISTOL, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- VanderbiltReport.com, a financial news…

3 months ago

Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groupsBoth…

3 months ago

Albany Gains New Mental Health Resource as Rivia Mind Opens New Office

ALBANY, NEW YORK / ACCESS Newswire / September 23, 2025 / Rivia Mind, a mental health practice providing compassionate, evidence-based…

3 months ago

CBD Life Sciences Inc. (CBDL) Announces LOI With New Jersey Dispensary, Unlocking New Revenue Channels & Strategic Growth Opportunities

Strategic collaboration expands CBDL's footprint in the booming East Coast cannabis market projected to surpass $33 billion by 2030, while…

3 months ago

Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay

First and only in-clinic multiplexed Cobalamin & Folate assay now validated for feline patients ANN ARBOR, MI / ACCESS Newswire…

3 months ago

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic…

3 months ago

Reviva to Participate in the Lytham Partners Fall 2025 Investor Conference

CUPERTINO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage…

3 months ago

Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%

Important ophthalmic treatment for patients and expected to be a key growth driver for Amneal’s Affordable Medicines segmentBRIDGEWATER, N.J., Sept.…

3 months ago